Physician profile
Kim L Romansky
NPI 1093318685
$1,196.63
in general payments reported to CMS, 2019-2025
18 companies · $310 in 2025
The $310 reported for 2025 was more than what a typical Primary Care provider received nationally (typical 2025 total: $170).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $40.09 · 2023: $198 · 2024: $649 · 2025: $310.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,157.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,156.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $205.79 | 2023-2024 | Ozempic, Rybelsus |
| Abbvie INC. | $160.02 | 2023-2024 | |
| Pfizer INC. | $139.22 | 2024-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $123.12 | 2025 | Jardiance |
| Inspire Medical Systems, INC. | $120.16 | 2023-2025 | Inspire |
| Amgen INC. | $99.73 | 2023-2024 | Repatha, Otezla, Evenity |
| Viiv Healthcare Company | $55.40 | 2024 | Apretude |
| Biohaven Pharmaceutical Holding Company LTD. | $40.09 | 2022 | |
| Sumitomo Pharma America, INC. | $36.28 | 2024-2025 | Gemtesa |
| Astrazeneca Pharmaceuticals LP | $34.63 | 2024-2025 | Airsupra |
| Agios Pharmaceuticals, INC. | $28.86 | 2024 | Pyrukynd |
| Heartflow, INC. | $28.73 | 2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $26.87 | 2024 | |
| Tactile Systems Technology INC | $23.90 | 2025 | Flexitouch Plus, Nimbl |
| Esperion Therapeutics, INC. | $20.75 | 2024 | Nexletol |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $19.32 | 2025 | |
| E.R. Squibb & Sons, L.L.C. | $17.27 | 2024 | Eliquis |
| Merck Sharp & Dohme LLC | $16.49 | 2024 | Capvaxive |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kim Romansky listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.